Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study

[1]  A. Streinu-Cercel,et al.  Insulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional study , 2013, BMC Endocrine Disorders.

[2]  I. Ofotokun,et al.  HIV: Inflammation and Bone , 2012, Current HIV/AIDS Reports.

[3]  P. Sax,et al.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. , 2011, The Journal of infectious diseases.

[4]  L. Lynen,et al.  Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen , 2010, AIDS research and therapy.

[5]  T. Brown,et al.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D , 2010, Antiviral therapy.

[6]  M. King,et al.  Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen , 2009, Journal of acquired immune deficiency syndromes.

[7]  M. Re,et al.  Metabolic bone disease in HIV infection , 2009, AIDS.

[8]  C. Katlama,et al.  Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. , 2009, AIDS.

[9]  L. Lynen,et al.  Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome? , 2009, AIDS research and therapy.

[10]  G. Robbins,et al.  High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. , 2009, AIDS research and human retroviruses.

[11]  T. Brown,et al.  Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. , 2008, The Journal of clinical endocrinology and metabolism.

[12]  S. Lawson-Ayayi,et al.  Reduced bone mineral density in HIV-infected patients: prevalence and associated factors , 2008, AIDS.

[13]  C. Delpierre,et al.  Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. , 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[14]  Jack Wang,et al.  Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strategy , 2007, Journal of acquired immune deficiency syndromes.

[15]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[16]  S. Grinspoon,et al.  Longitudinal analysis of bone density in human immunodeficiency virus-infected women. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  S. Ballinger,et al.  Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti‐Retroviral Therapy for AIDS , 2006, Annals of the New York Academy of Sciences.

[18]  M. Saag,et al.  Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. , 2006, AIDS research and human retroviruses.

[19]  A. Sommet,et al.  Total body composition by DXA of 241 HIV-negative men and 162 HIV-infected men: proposal of reference values for defining lipodystrophy. , 2005, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[20]  E. Seminari,et al.  Osteoprotegerin and bone turnover markers in heavily pretreated HIV‐infected patients , 2005, HIV medicine.

[21]  I. Schiefke,et al.  Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. , 2005, World journal of gastroenterology.

[22]  E. Shane,et al.  Bone mass and mineral metabolism in HIV+ postmenopausal women , 2005, Osteoporosis International.

[23]  Masaki Noda,et al.  Leptin regulation of bone resorption by the sympathetic nervous system and CART , 2005, Nature.

[24]  Pascal G. P. Martin,et al.  Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. , 2005, The Journal of clinical investigation.

[25]  S. Mora.  Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls: use of correlation analyses. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[27]  H. Suominen,et al.  Relationship of sex hormones to bone geometric properties and mineral density in early pubertal girls. , 2004, The Journal of clinical endocrinology and metabolism.

[28]  F. Chessa,et al.  Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[29]  C. Baudoin,et al.  BMD Is Reduced in HIV‐Infected Men Irrespective of Treatment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  J. Laurence,et al.  HIV Envelope gp120-mediated Regulation of Osteoclastogenesis via Receptor Activator of Nuclear Factor κB Ligand (RANKL) Secretion and Its Modulation by Certain HIV Protease Inhibitors through Interferon-γ/RANKL Cross-talk* , 2003, Journal of Biological Chemistry.

[31]  L. Bergoglio,et al.  Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy , 2003, AIDS.

[32]  David A. Cooper,et al.  Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy , 2003, AIDS.

[33]  R. Bretzel,et al.  Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. , 2003, The Journal of infection.

[34]  K. Yarasheski,et al.  HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D , 2003, AIDS.

[35]  T. Buchanan,et al.  Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  A. Gianoukakis,et al.  Ritonavir-associated hyperparathyroidism, osteopenia and bone pain. , 2002, AIDS.

[37]  S. Mallal,et al.  Getting to the HAART of insulin resistance. , 2001, AIDS.

[38]  S. Mora,et al.  Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy , 2001, AIDS.

[39]  C. Vigouroux,et al.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.

[40]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[41]  J. Silver,et al.  Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. , 1999, Kidney international. Supplement.

[42]  P. Reiss,et al.  Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy , 1999, The Lancet.

[43]  Xiao-peng Yu,et al.  Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription. , 1997, Endocrinology.

[44]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[45]  L. Olansky,et al.  Parathyroid hormone stimulation of alkaline phosphatase activity in cultured neonatal mouse calvarial bone cells: Involvement of cyclic AMP and calcium , 1986, Journal of cellular physiology.

[46]  D. Strait,et al.  Healthcare Systems , 1988, Symposium Record Policy Issues in Information and Communication Technologies in Medical Applications.